Skip to content

Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse

Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse: a Nationwide Multicenter Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03917056
Enrollment
1000
Registered
2019-04-16
Start date
2019-06-24
Completion date
2025-03-27
Last updated
2024-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Internal Hemorrhoid, Rectal Prolapse

Keywords

Cap-assisted endoscopic sclerotherapy, Internal Hemorrhoid, Rectal Prolapse

Brief summary

This clinical trial aims to evaluate the efficacy and safety of long needle and short needle in the treatment of internal hemorrhoids and rectal prolapse through CAES (Cap-assisted endoscopic sclerotherapy).

Detailed description

Traditional endoscopic sclerotherapy for internal hemorrhoids require retroflection of the endoscope. Retroflection of the endoscope has blind areas and affects the precise operation. And, short-needle injection can easily lead to artificial ulcer and secondary bleeding. CAES is a new, minimally invasive endoscopic technique for the treatment of internal hemorrhoids and rectal prolapse. CAES was performed based on the requirement of the cap, endoscope, disposable endoscopic long injection needle, enough insufflated air and sclerosing agent. It can accurately control the injection angle, direction and depth under direct vision, and avoid iatrogenic injury caused by ectopic injection to the greatest possible extent. To investigate the effect of long needle and short needle on the outcome of CAES, participants with internal hemorrhoids and rectal prolapse were randomly assigned to a long needle group and a short needle group using a prospective, randomized, controlled study at multiple centers in China. The efficacy, adverse events and satisfaction of the two groups were observed.

Interventions

PROCEDURECap-assisted endoscopic sclerotherapy using long needle

Participants were treated with CAES using long needle.

PROCEDURECap-assisted endoscopic sclerotherapy using short needle

Participants were treated with CAES using short needle.

Sponsors

The Second Hospital of Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients with internal hemorrhoids and rectal prolapse, combined with external hemorrhoids or without external hemorrhoids. 2. Patients with bowel preparation.

Exclusion criteria

1. History of anoscopic/endoscopic sclerotherapy. 2. Patients with acute thrombotic external hemorrhoids. 3. Patients with serious internal hemorrhoids of grade IV. 4. Patients with anal stenosis, anal fissure, fistula, fecal incontinence, ulcerative colitis, Crohn's disease. 5. Patients with acute diarrhea in the past 24 hours. 6. Hypertensive patients with uncontrolled blood pressure, patients with cerebrovascular accident and obvious bleeding tendency, pregnant women, mental disorders and decompensated cirrhosis.

Design outcomes

Primary

MeasureTime frameDescription
Recurrence rate24 weeksRecurrence rate defined as the proportion of patients with recurrent hemorrhoids at 24 weeks post-CAES, as derived from patients' self-reported answer. Patients will be considered to have recurrent hemorrhoids when any of the following are recorded: (1)Unchanged or worse compared with before starting treatment at 24th week as reported by the patient, or (2) seeking repeat CAES treatment, alternative non-surgical/surgical treatments for internal hemorrhoids within 24weeks (except medication treatment), or (3) presence of any symptoms or events that strongly indicated recurrent hemorrhoids among patients not meeting (1) or (2).

Secondary

MeasureTime frameDescription
Symptoms of prolapse1day, 7days, 14days and 24 weeksThere are three degrees of prolapse: 1. No prolapse; 2: occasionally; 3: quite often.
Symptoms of anal pain1day, 7days, 14days and 24 weeksNRS pain digital rating scale was adopted, that is, 0-10 was used to represent different degrees of pain, 0 was painless, and 10 was severe pain. 0 painless, 1-3 mild pain (pain does not affect sleep), 4-6 moderate pain, 7-9 severe pain (inability to fall asleep or waking up during sleep), 10 severe pain.
EQ-5D health scale scores24 weeksBefore CAES and after CAES, EQ-5D health scale scores were performed.
Symptoms of anal bleeding1day, 7days, 14days and 24 weeksBleeding is divided into three degrees: 1. No bleeding; 2. 2: occasionally; 3: quite often.
Satisfaction degree24 weeksNumber of satisfied participants
Symptom severity score1day and 24 weeksfive questions about hemorrhoidal symptoms (anal pain, prolapse, itching, soiling, and blood loss) will be self-assessed by patients by answering how often each symptom was encountered (never, sometimes, weekly, or daily). The score is the sum of the points from all five questions, ranging from 0 to 15 points, where an increase in number is an increase in symptom.
Adverse events and serious adverse events1day, 7days, 14days and 24 weeksAdverse events included bleeding, anal pain, and dyspnea.Serious adverse events include serious complications directly or indirectly related to the operation, such as death, bleeding, perforation, etc.

Countries

China

Contacts

Primary ContactFaming Zhang, MD,PhD
fzhang@njmu.edu.cn86-25-58509883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026